Cenix to Help Regulus Develop Targets for miRNA-Based Drugs | GenomeWeb
NEW YORK (GenomeWeb News) – Cenix BioScience said today that it has agreed to help Regulus Therapeutics develop its miRNA modulators for immunology and inflammation therapeutics. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.